Viking Therapeutics (VKTX) Cash from Operations (2016 - 2025)
Historic Cash from Operations for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$94.0 million.
- Viking Therapeutics' Cash from Operations fell 32802.57% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.6 million, marking a year-over-year decrease of 20246.33%. This contributed to the annual value of -$87.8 million for FY2024, which is 1964.4% down from last year.
- As of Q3 2025, Viking Therapeutics' Cash from Operations stood at -$94.0 million, which was down 32802.57% from -$47.1 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Cash from Operations registered a high of -$6.1 million during Q1 2024, and its lowest value of -$94.0 million during Q3 2025.
- Moreover, its 5-year median value for Cash from Operations was -$13.5 million (2022), whereas its average is -$23.7 million.
- As far as peak fluctuations go, Viking Therapeutics' Cash from Operations skyrocketed by 7510.86% in 2024, and later plummeted by 75313.01% in 2025.
- Quarter analysis of 5 years shows Viking Therapeutics' Cash from Operations stood at -$12.4 million in 2021, then increased by 11.53% to -$10.9 million in 2022, then plummeted by 61.45% to -$17.6 million in 2023, then tumbled by 76.76% to -$31.2 million in 2024, then plummeted by 201.48% to -$94.0 million in 2025.
- Its last three reported values are -$94.0 million in Q3 2025, -$47.1 million for Q2 2025, and -$52.3 million during Q1 2025.